Where can I find the protein concentration?

The protein concentration of each product is listed on the Certificate of Analysis. This value is determined for each individual lot and reflects the actual concentration (mg/mL) of the material you received.

Where can I find the recommended storage conditions?

Storage conditions are listed on both the product datasheet and the Certificate of Analysis. These recommendations are based on internal stability assessments and are intended to maintain protein integrity and activity.

What should I do if my product arrives warm, partially thawed, or damaged?

Please contact Athens Bioscience with your order number and lot number. Our technical support team will assist you promptly.

Where can I find the final buffer composition?

The final buffer formulation is provided on the Certificate of Analysis. This includes buffer components, pH, and whether the product was supplied as a liquid or lyophilized powder.

Lipoprotein a, [Lp(a)]

Name: Lipoprotein a, [Lp(a)]
SKU: 12-16-121601-100UG
Availability: InStock

Lp(a)

A LDL-like lipoprotein particle which is a strong risk factor for cardiovascular disease when plasma levels are elevated as it promotes inflammation and plaque formation.

Purity: ≥95% (by electrophoresis)

Source: Human Plasma

Molecular Weight: 280 - 700 kDa

Form: Liquid

View All Specifications

Product Description

Role of protein in biology

Lipoprotein(a), or Lp(a), is a specialized lipoprotein particle found in plasma at concentrations typically ranging from 20 to 760 mg/L, with levels largely determined by genetic factors 1. Structurally, Lp(a) consists of an LDL-like core bound to apolipoprotein(a), which imparts unique proatherogenic and prothrombotic properties.

Common research uses

Elevated Lp(a) is an independent and causal risk factor for atherosclerotic cardiovascular diseases, including coronary artery disease, heart attack, stroke, aortic stenosis, and peripheral artery disease. Lp(a) promotes vascular inflammation and plaque formation by accumulating in vessel walls and carrying oxidized phospholipids, which trigger inflammatory responses and calcification. It also interferes with fibrinolysis, increasing the risk of thrombosis. Currently, no FDA-approved therapies specifically target Lp(a) reduction, but its measurement can help identify individuals at high cardiovascular risk who may benefit from intensified preventive strategies. Research into targeted Lp(a)-lowering treatments is ongoing, offering hope for future clinical applications.

Common uses include IVD Assay standards, calibrators and controls, therapeutics research, cardiovascular research.